Rigel Pharmaceuticals, Inc.

NasdaqGS:RIGL Voorraadrapport

Marktkapitalisatie: US$239.8m

Rigel Pharmaceuticals Beheer

Beheer criteriumcontroles 2/4

De CEO Rigel Pharmaceuticals is Raul Rodriguez, benoemd in May2010, heeft een ambtstermijn van 14.5 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 3.44M, bestaande uit 21.2% salaris en 78.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.75% van de aandelen van het bedrijf, ter waarde $ 1.79M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.5 jaar en 6.3 jaar.

Belangrijke informatie

Raul Rodriguez

Algemeen directeur

US$3.4m

Totale compensatie

Percentage CEO-salaris21.2%
Dienstverband CEO14.5yrs
Eigendom CEO0.7%
Management gemiddelde ambtstermijn3.5yrs
Gemiddelde ambtstermijn bestuur6.3yrs

Recente managementupdates

Recent updates

Rigel Pharma Remains Bullish, Growth Fueled By FDA-Approved Drugs, Strategic Partnerships

Oct 10

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Fly 31% But Investors Aren't Buying For Growth

Sep 25
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Fly 31% But Investors Aren't Buying For Growth

There's No Escaping Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Muted Revenues Despite A 29% Share Price Rise

Jul 30
There's No Escaping Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Muted Revenues Despite A 29% Share Price Rise

Rigel Pharmaceuticals: Undervalued FDA-Approved Products With Promising Cash Flow Potential

Jul 24

Little Excitement Around Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Revenues As Shares Take 29% Pounding

May 01
Little Excitement Around Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Revenues As Shares Take 29% Pounding

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Mar 08
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Surges 36% Yet Its Low P/S Is No Reason For Excitement

Mar 04
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Surges 36% Yet Its Low P/S Is No Reason For Excitement

Rigel Pharmaceuticals: Upgrading To A 'Top Idea' Ahead Of Promising Q4/2023 Earnings Report

Feb 23

Lacklustre Performance Is Driving Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Low P/S

Jan 15
Lacklustre Performance Is Driving Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Low P/S

Is Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Trading At A 25% Discount?

Oct 25
Is Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Trading At A 25% Discount?

Rigel cutting 16% of workforce after declining to file sNDA for fostamatinib

Oct 10

Rigel Pharma adds ~7% to reach over two month high

Aug 18

Rigel rises 17% on strong Q2 result

Aug 03

Rigel Pharmaceuticals: A Status Check

May 31

Is Rigel Pharmaceuticals (NASDAQ:RIGL) A Risky Investment?

Apr 21
Is Rigel Pharmaceuticals (NASDAQ:RIGL) A Risky Investment?

Rigel Pharmaceuticals: Why The Stock Is On A Run

Mar 21

What Does The Future Hold For Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)? These Analysts Have Been Cutting Their Estimates

Mar 06
What Does The Future Hold For Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)? These Analysts Have Been Cutting Their Estimates

Analyse CEO-vergoeding

Hoe is Raul Rodriguez's beloning veranderd ten opzichte van Rigel Pharmaceuticals's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-US$14m

Mar 31 2024n/an/a

-US$20m

Dec 31 2023US$3mUS$728k

-US$25m

Sep 30 2023n/an/a

-US$24m

Jun 30 2023n/an/a

-US$38m

Mar 31 2023n/an/a

-US$45m

Dec 31 2022US$3mUS$700k

-US$59m

Sep 30 2022n/an/a

-US$83m

Jun 30 2022n/an/a

-US$85m

Mar 31 2022n/an/a

-US$85m

Dec 31 2021US$3mUS$662k

-US$18m

Sep 30 2021n/an/a

-US$15m

Jun 30 2021n/an/a

-US$8m

Mar 31 2021n/an/a

-US$11m

Dec 31 2020US$3mUS$662k

-US$30m

Sep 30 2020n/an/a

-US$28m

Jun 30 2020n/an/a

-US$25m

Mar 31 2020n/an/a

-US$28m

Dec 31 2019US$3mUS$649k

-US$67m

Sep 30 2019n/an/a

-US$46m

Jun 30 2019n/an/a

-US$59m

Mar 31 2019n/an/a

-US$64m

Dec 31 2018US$4mUS$637k

-US$70m

Sep 30 2018n/an/a

-US$100m

Jun 30 2018n/an/a

-US$93m

Mar 31 2018n/an/a

-US$87m

Dec 31 2017US$2mUS$618k

-US$78m

Compensatie versus markt: De totale vergoeding ($USD 3.44M ) Raul } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 1.46M ).

Compensatie versus inkomsten: De vergoeding van Raul is gestegen terwijl het bedrijf verliesgevend is.


CEO

Raul Rodriguez (63 yo)

14.5yrs

Tenure

US$3,440,790

Compensatie

Mr. Raul R. Rodriguez has been the Chief Executive Officer and Director of Rigel Pharmaceuticals, Inc., since November 2014 and its President since May 2010. Mr. Rodriguez served as Chief Operating Officer...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Raul Rodriguez
President14.5yrsUS$3.44m0.75%
$ 1.8m
Dean Schorno
Executive VP & CFO6.5yrsUS$1.21m0.069%
$ 165.8k
Raymond Furey
Executive VP1.9yrsUS$683.00k0.0028%
$ 6.8k
David Santos
Executive VP & Chief Commercial Officer4.3yrsUS$1.34m0.031%
$ 75.1k
Julie Patel
Senior VP of Human Resources2.8yrsgeen gegevensgeen gegevens
Esteban Masuda
Executive Vice President of Research8.2yrsUS$796.09kgeen gegevens
Joseph Lasaga
Executive VP & Chief Business Officerless than a yeargeen gegevensgeen gegevens
Lisa Rojkjaer
Executive VP & Chief Medical Officerless than a yeargeen gegevensgeen gegevens
Tarek Sallam
Vice President of Marketingno datageen gegevensgeen gegevens

3.5yrs

Gemiddelde duur

61yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van RIGL wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.5 jaar).


Bestuursleden

NaamPositieTenureCompensatieEigendom
Raul Rodriguez
President10yrsUS$3.44m0.75%
$ 1.8m
Walter Moos
Independent Director27.7yrsUS$138.58k0.044%
$ 105.3k
Jane Wasman
Independent Director5.7yrsUS$145.58k0.043%
$ 102.2k
Gregory Lapointe
Independent Chairman of the Board7yrsUS$190.58k0.043%
$ 102.2k
Kamil Ali-Jackson
Independent Director2.9yrsUS$140.58k0.025%
$ 59.6k
Alison Hannah
Independent Director3.5yrsUS$212.98k0.032%
$ 76.7k

6.3yrs

Gemiddelde duur

65yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van RIGL wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.3 jaar).